title: [Evaluation of thrombolytic therapy by pulmonary radionuclide perfusion imaging in patients with acute pulmonary thromboembolism].
abstract: OBJECTIVE
  To assess the change of pulmonary perfusion after thrombolytic therapy in patients with acute pulmonary embolism.
  
  
  METHODS
  Eighty patients with acute pulmonary embolism received pulmonary radionuclide perfusion imaging before and after thrombolytic therapy. Percentage of perfusion defect scores (PPDs) was calculated by semiquantitative analysis of pulmonary perfusion imaging before thrombolytic therapy (PPDsD(0)), 1 - 5 days (PPDsD(5)), 6 - 30 days (PPDsD(30)) and 3 months after thrombolytic therapy (PPDsM(3)).
  
  
  RESULTS
  The mean PPDsD(0) of the 80 patients was (57.3 +/- 16.4)%. In 64 of the 80 patients, mean PPDsD(0) and PPDsD(5) were (55.5 +/- 16.8)% and (40.0 +/- 18.6)% respectively (P < 0.001). In 30 of these 64 patients, mean PPDsD(0), PPDsD(5) and PPDsD(30) were (57.5 +/- 16.1)%, (39.3 +/- 16.8)% and (29.5 +/- 17.3)% respectively. Differences between these 3 mean PPDs values were highly significant (all P < 0.001). In 11 of the 80 patients, mean PPDsD(30) and PPDsM(3) were (40.9 +/- 18.1)% and (29.1 +/- 27.1)% respectively (P < 0.05). In two groups of patients with the courses of disease in 7 days and in 8 - 14 days respectively, significant differences were found between PPDsD(0) and PPDsD(5) (P < 0.001, P < 0.001 respectively), and between PPDsD(0) and PPDsD(30) (P < 0.001, P < 0.005 respectively). The difference was also significant, although to a lesser degree (P < 0.05) between these values in a group of patients with the course of disease beyond 14 days.
  
  
  CONCLUSIONS
  This study suggests that radionuclide pulmonary perfusion imaging is a reliable method for evaluating the changes of pulmonary perfusion before and after thrombolytic therapy in patients with acute pulmonary embolism.
authors.affiliation: Fuwai Cardiovascular Hospital, Peking Union Medical College & Chinese Academy of Medical Sciences, Beijing 100037, China.
authors.forename: Wei
authors.initials: W
authors.lastname: Fang
authors.forename: Rong-fang
authors.initials: RF
authors.lastname: Shi
authors.forename: Xiu-jie
authors.initials: XJ
authors.lastname: Liu
authors.forename: Xian-sheng
authors.initials: XS
authors.lastname: Cheng
authors.forename: Bai-ping
authors.initials: BP
authors.lastname: Chen
authors.forename: Zhi-hong
authors.initials: ZH
authors.lastname: Liu
mesh_terms: D000208:Acute Disease; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D005260:Female; D005343:Fibrinolytic Agents / Q000627:therapeutic use; D006801:Humans; D008168:Lung / Q000000981:diagnostic imaging*; D008297:Male; D008875:Middle Aged; D011655:Pulmonary Embolism / Q000000981:diagnostic imaging* / Q000188:drug therapy; D011877:Radionuclide Imaging; D019275:Radiopharmaceuticals; D011994:Recombinant Proteins / Q000627:therapeutic use; D013668:Technetium Tc 99m Aggregated Albumin; D015912:Thrombolytic Therapy; D010959:Tissue Plasminogen Activator / Q000627:therapeutic use; D016896:Treatment Outcome; D014568:Urokinase-Type Plasminogen Activator / Q000627:therapeutic use; D014692:Ventilation-Perfusion Ratio
chemical_list: D005343:Fibrinolytic Agents; D019275:Radiopharmaceuticals; D011994:Recombinant Proteins; D013668:Technetium Tc 99m Aggregated Albumin; D010959:Tissue Plasminogen Activator; D014568:Urokinase-Type Plasminogen Activator